您要查找的是不是：
- Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用?
- Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
- The structures and functions of EGFR as well as current status of EGFR tyrosine kinase inhibitors are reviewed. 综述了EGFR的结构和作用以及近年来EGFR酪氨酸激酶抑制剂的研究进展。
- Genistein, the tyrosine kinase inhibitors, plays the effect by an inhibiton of tyrosine phosphorlation. Genistein是酪氨酸激酶的非特异性抑制剂，通过抑制酪氨酸的磷酸化而发挥作用。
- The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文综述了近年来酪氨酸激酶抑制剂的研究进展，包括抑制剂的结构和与激酶作用的药效团模型。
- Response rates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in cancer treatment have been surprisingly and disappointingly low. EGFR酪氨酸激酶抑制剂在肿瘤的治疗中的反应率是出乎意料和令人失望的低。
- We detected the T790M mutation, which confers drug resistance, in circulating tumor cells collected from patients with EGFR mutations who had received tyrosine kinase inhibitors. 在从接受酪氨酸激酶抑制剂治疗患者中收集的循环肿瘤细胞中，我们检测到了引起耐药的T790M突变，
- A 3D database searching was conducted with 3DFS in 3D database using the pharmacophore of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 摘要用表皮生长因子受体酪氨酸激酶抑制剂的药效团作为提问结构在三维数据库中进行了搜索。
- Objective To build 3D-pharmacophore model of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors using distance comparisons method and design novel EGFR inhibitors. 目的构建表皮生长因子受体(EGFR)抑制剂的药效团模型,设计新结构类型的化合物。
- Gefitinib, the first EGFR tyrosine kinase inhibitor put into clinical trial, was put into market in Japan in 2002. 吉非替尼是EGFR酪氨酸激酶抑制剂中最早进入临床试验的口服药物，2002年首次于日本上市。
- EGFR tyrosine kinase inhibitor is an investigative hot spot in targeted therapy of non-small cell lung cancer (NSCLC). 摘要EGFR靶向抑制剂，是目前NSCLC靶向治疗的研究热点之一。
- Gefitinib (Iressa, ZD1839), a specific tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), is a novel molecular-targeting antineoplastic agent. 摘要吉非替尼是一种新型的分子靶向抗癌药物，它选择性抑制表皮生长因子受体酪氨酸激酶而发挥作用。
- Objective To assess the effect of tyrosine kinase inhibitor (2,5-MC) on the inhibition of in-stent inti-mal hyperplasia. 目的评估酪氨酸蛋白激酶抑制剂2,5-MC抑制支架植入术后内膜增殖的效果。
- CONCLUSIONS. In the absence of therapy with tyrosine kinase inhibitors, recurrence in completely resected primary GIST is independently predicted by mitotic rate, tumor size, and tumor location. 结论：用没有酪氨酸激酶抑制剂治疗的情况下，原发性GIST完全切除后的复发率由有丝分裂率、肿瘤大小和肿瘤部位决定。
- HTS model for protein tyrosine kinase inhibitors 酪氨酸蛋白激酶抑制剂的高通量筛选模型
- Progress in Tyrosine Kinase Inhibitor 酪氨酸激酶抑制剂的研究新进展
- protein tyrosine kinase inhibitor 酪氨酸蛋白激酶抑制剂
- Receptor tyrosine kinase inhibitor 受体酪氨酸激酶抑制剂
- Sunitinib: a novel multitargeted receptor tyrosine kinase inhibitor 新型多靶点酪氨酸激酶抑制剂苏尼替尼的研究进展
